CN111297912A - Application of lactobacillus plantarum TWK10 in preparing anti-post-exercise inflammation or body fat reducing composition - Google Patents
Application of lactobacillus plantarum TWK10 in preparing anti-post-exercise inflammation or body fat reducing composition Download PDFInfo
- Publication number
- CN111297912A CN111297912A CN201811519327.4A CN201811519327A CN111297912A CN 111297912 A CN111297912 A CN 111297912A CN 201811519327 A CN201811519327 A CN 201811519327A CN 111297912 A CN111297912 A CN 111297912A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- composition
- milk
- probiotic composition
- twk10
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 41
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 41
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 41
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 39
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 36
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 34
- 230000001603 reducing effect Effects 0.000 title claims abstract description 15
- 239000006041 probiotic Substances 0.000 claims abstract description 55
- 235000018291 probiotics Nutrition 0.000 claims abstract description 55
- 230000000529 probiotic effect Effects 0.000 claims abstract description 48
- 239000002775 capsule Substances 0.000 claims abstract description 14
- 235000013336 milk Nutrition 0.000 claims abstract description 14
- 239000008267 milk Substances 0.000 claims abstract description 14
- 210000004080 milk Anatomy 0.000 claims abstract description 14
- 238000004321 preservation Methods 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 12
- 235000013618 yogurt Nutrition 0.000 claims abstract description 12
- 239000007937 lozenge Substances 0.000 claims abstract description 11
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 9
- 235000013402 health food Nutrition 0.000 claims abstract description 8
- 235000013322 soy milk Nutrition 0.000 claims abstract description 8
- 235000015203 fruit juice Nutrition 0.000 claims abstract description 7
- 239000003826 tablet Substances 0.000 claims abstract description 7
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- 235000013351 cheese Nutrition 0.000 claims abstract description 6
- 235000009508 confectionery Nutrition 0.000 claims abstract description 6
- 235000013365 dairy product Nutrition 0.000 claims abstract description 6
- 239000003085 diluting agent Substances 0.000 claims abstract description 6
- 239000006187 pill Substances 0.000 claims abstract description 6
- 239000000725 suspension Substances 0.000 claims abstract description 6
- 239000006188 syrup Substances 0.000 claims abstract description 6
- 235000020357 syrup Nutrition 0.000 claims abstract description 6
- 235000008452 baby food Nutrition 0.000 claims abstract description 5
- 229940112822 chewing gum Drugs 0.000 claims abstract description 5
- 235000015218 chewing gum Nutrition 0.000 claims abstract description 5
- 239000000839 emulsion Substances 0.000 claims abstract description 5
- 235000015243 ice cream Nutrition 0.000 claims abstract description 5
- 235000015110 jellies Nutrition 0.000 claims abstract description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 238000009629 microbiological culture Methods 0.000 claims abstract description 4
- 235000011496 sports drink Nutrition 0.000 claims abstract description 4
- 235000015140 cultured milk Nutrition 0.000 claims abstract 3
- 241000894006 Bacteria Species 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 16
- 210000004698 lymphocyte Anatomy 0.000 claims description 12
- 241000186660 Lactobacillus Species 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 210000000440 neutrophil Anatomy 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 229940039696 lactobacillus Drugs 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 241000194017 Streptococcus Species 0.000 claims description 4
- 235000021185 dessert Nutrition 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 239000008274 jelly Substances 0.000 claims description 4
- 235000015192 vegetable juice Nutrition 0.000 claims description 4
- 241000194033 Enterococcus Species 0.000 claims description 3
- 241000194036 Lactococcus Species 0.000 claims description 3
- 241000192132 Leuconostoc Species 0.000 claims description 3
- 241000192001 Pediococcus Species 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 231100000225 lethality Toxicity 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 abstract description 3
- 239000000243 solution Substances 0.000 abstract description 3
- 235000020186 condensed milk Nutrition 0.000 abstract 1
- 235000011850 desserts Nutrition 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 description 11
- 230000006020 chronic inflammation Effects 0.000 description 11
- 230000008859 change Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000209149 Zea Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 235000019985 fermented beverage Nutrition 0.000 description 2
- -1 glidants (glidants) Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000131482 Bifidobacterium sp. Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 241001495410 Enterococcus sp. Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- 241000178948 Lactococcus sp. Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010061223 Ligament injury Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 241000604136 Pediococcus sp. Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 208000021945 Tendon injury Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000522649 Zornia Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
Abstract
The invention provides an application of lactobacillus plantarum TWK10 in preparing a probiotic composition for improving inflammation after exercise or reducing body fat, wherein the lactobacillus plantarum TWK10 is preserved in China general microbiological culture Collection center (CGMCC), and the preservation number is CGMCC 13008; the probiotic composition, including pharmaceutically acceptable carriers, excipients, diluents, is in the form of a solution, suspension, emulsion, powder, lozenge, pill, syrup, lozenge, tablet, chewing gum, puree, and capsule, and may be further formulated into dairy products, condensed milk, yogurt milk, frozen yogurt, fermented milk beverages, milk powder, ice cream, cheese, soy milk, fermented soy milk, fruit juice, sports drinks, desserts, jellies, candies, infant food, health food, animal feed, herbal compositions, dietary supplements.
Description
[ technical field ] A method for producing a semiconductor device
The invention relates to the field of probiotic application, in particular to lactobacillus plantarum for resisting inflammation after exercise or reducing body fat.
[ Prior Art ]
The probiotics has natural sources, no harm to human bodies, low threshold of taking and various health care and regulation effects, so the probiotics is popular in the market of health food. Among them, Lactobacillus plantarum (Lactobacillus plantarum) is a common probiotic, a gram-positive bacterium, found in fermented foods or animal saliva, has the largest gene in Lactobacillus, and has many variations, so that the same strain may show different characteristics and efficacies due to different variation degrees and adaptation conditions.
Previously, Lactobacillus plantarum has been reported to have a variety of medical uses, including protection against viral infections of the respiratory tract, and increased susceptibility of cancer cells to drugs when mixed with chemotherapeutic drugs, as well as various uses for food supplements, such as prevention of toxic fungi growing in corn.
Inflammation refers to a defensive primary response of living tissues having a vascular system to inflammatory factors and local injury, and can be classified into acute inflammation and chronic inflammation. Acute inflammation is the preliminary reaction of an organism to a noxious stimulus, with more plasma and leukocytes (especially granulocytes) migrating from the blood to the damaged tissue, and undergoing a series of linked reactions involving the local vascular system, immune system, and individual cells within the damaged tissue. Chronic inflammation results in a change in the cell type at the site of inflammation, which allows tissue destruction and repair to occur simultaneously. In addition, human fat has the ability to secrete inflammatory hormones, so body fat excess is also a factor in chronic inflammation of the body. In some special cases, inflammation may even cause allergy to the body's own immune system, which in turn attacks its tissues and cells, such as: allergic diseases of immune system such as rheumatoid arthritis and lupus erythematosus. Chronic inflammation can cause a series of diseases, which can gradually lead to organ and tissue dysfunction, easily cause fatigue, aging and hormone imbalance, and also cause various serious diseases, including hepatitis, pneumonia, nephritis, autoimmune diseases, arthritis, diabetes, alzheimer disease, cardiovascular diseases and even cancer.
The injury of muscle fiber or connective tissue after exercise can cause muscle inflammation, and the accompanying acid, pain, various discomforts and chronic inflammation caused by long-term accumulation can not only reduce the exercise will and life quality of people, but also cause exercise injury and posture change. Especially for athletes, how to effectively reduce the inflammation after exercise is a key factor for improving the efficiency of exercise and competition and reducing the injury of exercise.
Although the health food Linglan is full of eyes in the market, only five of them have anti-inflammatory effect (Table 1) approved by Taiwan Weifu department, aiming at regulating allergic constitution and resisting allergy. However, the mechanism of allergy is allergen-induced, sensitization leading to excessive stimulation of mast cells by immunoglobulins, in contrast to post-exercise inflammation (which is mainly tendon or ligament injury) corresponding to acute or chronic inflammation. At present, the application of probiotics in improving inflammation after exercise is still under study.
TABLE 1 — checklist of anti-inflammatory health foods approved by the food and drug administration of health and welfare
The prior literature discloses that Lactobacillus plantarum can be used to improve anti-inflammation related disorders, however, there is no disclosure related to probiotics that can improve post-exercise inflammation.
Therefore, how to provide a new application of probiotics for improving inflammation after exercise is a problem to be solved by the invention.
[ summary of the invention ]
The invention provides an application of lactobacillus plantarum TWK10 in preparing a probiotic composition for improving inflammation after exercise, wherein the lactobacillus plantarum TWK10 is stored in Taiwan food industry development research institute and has a preservation number of BCRC910734 and is stored in China general microbiological culture Collection center (CGMCC), and the preservation number of CGMCC 13008.
To achieve the above-mentioned objects, the Lactobacillus plantarum TWK10 improves post-exercise inflammation by decreasing the neutrophil/lymphocyte ratio (NLR) and the platelet/lymphocyte (PLR) ratio.
To achieve the above object, the Lactobacillus plantarum TWK10 is a viable or non-activated bacterium, and the non-activated bacterium is subjected to physical or chemical treatment, wherein the physical treatment includes thermal death. The Lactobacillus plantarum TWK10 is viable bacteria, and the dosage is greater than or equal to 3x1010CFU/day; wherein the dosage is more than 1x1011CFU/day, has better effect of improving inflammation after exercise.
The invention also provides an application of the medical or food composition for improving inflammation after sports, which comprises the lactobacillus plantarum TWK10 with the preservation number of CGMCC 13008.
The invention further provides an application of the probiotic composition for preparing the probiotic composition for improving diseases caused by the neutrophil/lymphocyte ratio and the platelet/lymphocyte ratio, which comprises the lactobacillus plantarum TWK10 with the preservation number of CGMCC 13008.
The invention provides an application of lactobacillus plantarum TWK10 in preparation of a probiotic composition for reducing body fat, wherein the lactobacillus plantarum TWK10 is stored in Taiwan food industry development research institute and has a preservation number of BCRC910734 and is stored in China general microbiological culture Collection center (CGMCC), and the preservation number of CGMCC 13008.
To achieve the above purpose, the lactobacillus plantarum TWK10 reduces body fat to reduce body fat of the whole body.
For the purpose of the invention, the probiotic bacteria contained in the probiotic composition are live bacteria, inactivated bacteria or a combination of the live bacteria and the inactivated bacteria; the Lactobacillus plantarum TWK10 is administered in a dose of 3x10 or more10CFU/day.
The invention further provides an application of the medical or food composition for preparing the body fat reducing, which comprises the lactobacillus plantarum TWK10 with the preservation number of CGMCC 13008.
The invention further provides application of the probiotic composition for preparing the probiotic composition for improving diseases caused by the overhigh body fat, which comprises the lactobacillus plantarum TWK10 with the preservation number of CGMCC 13008.
The probiotic compositions may comprise pharmaceutically acceptable carriers, excipients, diluents, and in a dosage form selected from the group consisting of solutions, suspensions, emulsions, powders, lozenges, pills, syrups, lozenges, tablets, chews, syrups, and capsules.
The probiotic composition can be further made into fluid dairy product, concentrated milk, yogurt, frozen yogurt, lactobacillus fermented beverage, milk powder, ice cream, cheese, soybean milk, fermented soybean milk, vegetable juice, fruit juice, sport beverage, dessert, jelly, candy, infant food, health food, animal feed, Chinese herbal medicine composition, and dietary supplement.
The probiotic composition comprises one or any combination of the following probiotic groups: lactobacillus species, lactococcus species, Pediococcus species, Leuconostoc species, enterococcus species, Streptococcus species, Bifurcate bacteria species, yeast.
One example of the present invention demonstrates the high dose group of TWK10 viable bacteria (3X 10)11CFU/day) and thermogenic killed groups can reduce the number of inflammation indicators (NLR and PLR), contribute to improving post-exercise inflammation, and can be applied to diseases or symptoms caused by NLR and PLR overhigh; another example demonstrates that TWK10, in either viable or non-viable form, has body fat lowering effect, and that viable bacterial groups, with increasing doses, have more pronounced body fat reduction, and have the potential to be applied to diseases or conditions caused by excess body fat, and to ameliorate chronic inflammation.
The new use of the probiotic provided by the invention has the advantages that:
(1) specific and novel
The TWK10 is provided for the first time to improve the symptoms of inflammation after exercise, is different from other probiotics aiming at inhibiting diseases caused by inflammation, and provides strict evidence of human clinical data; in addition, the body fat reducing effect is provided, and for athletes, the body fat reducing composition can be combined with the anti-inflammation after sports and comprehensively assist in improving physical functions.
(2) Wide application range
Since inflammation and body fat are both the cause or evaluation factor of common diseases or symptoms, the probiotic application of the invention is helpful for improving the diseases and symptoms caused by inflammation or body fat excess.
(3) Synergistic effect
TWK10 can reduce body fat, release inflammatory hormone due to fat, and can improve inflammation after exercise after long-term administration, and can achieve synergistic effect in improving chronic inflammation due to continuous reduction of body fat.
[ description of the drawings ]
FIG. 1 shows the change in the neutrophil/lymphocyte ratio after exercise when a probiotic composition of Lactobacillus plantarum TWK10 is administered.
FIG. 2 changes in platelet/lymphocyte ratio after exercise when a probiotic composition containing Lactobacillus plantarum TWK10 was administered.
Fig. 3 changes in body fat after exercise when a probiotic composition containing Lactobacillus plantarum TWK10 was administered.
[ detailed description ] embodiments
The present invention will be further described with respect to the following examples, which are merely illustrative of the meaning and spirit of the present invention and are not to be construed as limiting or interpreted as limiting the invention or to be limited to only those examples or modes.
All technical and scientific terms used herein in the specification and claims of this invention are defined in accordance with the following description unless otherwise defined. Where the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise; unless otherwise indicated, common techniques employed in the practice of the present invention may include clinical specimen collection and analysis, high performance liquid chromatography, protein chemistry, biochemistry, recombinant DNA techniques, pharmacological techniques; furthermore, the terms "comprising" and "including" are open-ended terms; unless otherwise indicated, the materials used in the present invention are readily available commercially.
The term "probiotic" refers to a microorganism that, when properly administered, provides a physiological health benefit to the subject, and which has no toxicity, intestinal adherence, and benefit; colony Forming Units (CFU) is a term for the total number of colonies of microorganisms such as bacteria, molds, yeasts, etc. in a unit volume; the term "composition" refers to a product resulting from mixing or combining more than one active ingredient; "carrier", "excipient", means a non-toxic compound or agent that functions to assist the absorption of a drug by a cell or tissue, and may be fragrances (aromatics), buffers, binders (binders), colorants, disintegrants, diluents, emulsifiers, extenders (extenders), odor modifiers, gelling agents, glidants (glidants), preservatives, skin penetration enhancers, co-solvents, stabilizers, suspending agents, sweeteners, tonicity agents (tonicity agents), viscosity enhancers, or any combination thereof; the term "diluent" refers to a solvent used for dilution prior to administration of the composition and may be used to stabilize the compound. The invention is used for dissolving buffer solution of salt and regulating and controlling pH value, including but not limited to Phosphate Buffer Solution (PBS); the term "effective amount" refers to an amount of a compound or drug sufficient to alleviate one or more symptoms of a disease or physiological condition after ingestion by a subject. For example, a therapeutically effective amount is an amount comprising a compound of the present invention that will significantly reduce a particular physiological marker in a clinical setting; the phrase "maximum oxygen uptake (abbreviated as VO)2max) "refers to the highest amount of oxygen that a person can consume or utilize by tissue cells when performing the most strenuous exercise at sea level; the term "endurance exercise capacity test with fixed strength and time" means a VO of 60%2Intensity above max was tested for exercise on a treadmill or (or bicycle) for at least 30 minutes.
The following examples are merely illustrative of the probiotic compositions used in the present invention, wherein the probiotic may be live or inactivated via thermal lethal or other physical or chemical means.
The Lactobacillus plantarum strain used in the invention is Lactobacillus plantarum TWK10
(TWK10 for short) is obtained by separating Zea Zornia from fermented cabbage in Taiwan, and is preserved in China general microorganism culture collection management center (address: No. 3 of Xilu No. 1 of Beijing Korean Suzhong, and postal code: 100101), the preservation number is CGMCC13008, and the preservation date is 2016, 9 and 13 days; and Taiwan financial corporation institute of food industry development research, its deposit number is BCRC 910734. The Lactobacillus plantarum TWK10 was classified and named Lactobacillus plantarum (Lactobacillus plantarum).
EXAMPLE I anti-inflammatory efficacy of Lactobacillus plantarum TWK10 (I) Experimental design and procedure
The experiment adopts double-blind cross design, the subject is between 20-40 years old, after two weeks of washing period, the administration of probiotics is continued for six weeks, and endurance exercise test with fixed intensity is applied on the day of beginning and ending administration according to maximum oxygen uptake (VO)2max, mL/kg/min) into 5 groups of 16 persons each, and testing blood to determine physiological factor change; the probiotic compositions were administered three times a day, one capsule at a time, in each group, with the following doses and strains listed:
(1) placebo group, placebo capsules (containing maltodextrin, lactose, microcrystalline α -cellulose) without TWK10 were taken 3 times daily and three meals were taken with warm boiled water.
(2) Low dose group-TWK 10 live bacteria recommended 1-fold dose group (TWK 10-L): 1 TWK10 Capsule containing 1x1010CFU, 3 granules daily, 3X1010CFU/day, is taken with warm boiled water after three meals.
(3) Medium dose group-TWK 10 live bacteria recommended 3-fold dose group (TWK 10-M): 1 TWK10 Capsule containing 3x1010CFU, 3 pieces daily, 9X1010CFU/day, is taken with warm boiled water after three meals.
(4) High dose group-TWK 10 live bacteria recommended 10-fold dose group (TWK 10-H): 1 TWK10 Capsule containing 1x1011CFU, 3 granules daily, 3X1011CFU/day, three meals after mealIt is administered with boiled water.
(5) TWK10 Thermomycete (TWK 10-HK): 1 TWK10 Thermophoretic dead bacteria capsule containing 1x1011CFU, 3 granules taken daily, three meals after meal, 3x1011CFU/day.
(II) results
After six weeks of analysis, each individual group showed changes in the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte (PLR) ratios, both of which represent the status of the lymphatic system in vivo, after a fixed intensity-time (120 min) endurance exercise test, and both of which are indicators of in vivo inflammation, and a decrease in one of the ratios was an indicator of improved inflammation, and even reported as an observation factor for cancer metastasis or other diseases, with the results shown in fig. 1 and 2, and the vertical axis indicates the amount of change in NLR or PLR measured relative to the start of the test.
The results show that TWK10 decreased NLR in the high, medium, low dose and thermonecrotizing groups, with the low dose and thermonecrotizing groups decreased by about 30-40 fold compared to placebo; the PLR part, high dose and thermolethal bacteria group can be reduced by 1.2-1.8 times compared with placebo group; in general, administration of TWK10 killed bacteria improved post-exercise inflammation, whereas daily administration of 3X1010The live TWK10 bacteria above CFU also has effect in improving inflammation after exercise, and if higher dosage is taken daily, the dosage is more than 9x1010Live bacteria of CFU, e.g. 1X1011Or 3x1011CFU can achieve better effect.
Example two body fat lowering efficacy of Lactobacillus plantarum TWK10
Since adipocytes secrete inflammatory hormones, which cause systemic inflammation, high body fat is also closely related to chronic inflammation. Next, it will be discussed whether TWK10 has body fat reducing effect in addition to improving the symptoms of post-exercise inflammation.
The experimental design and the process are the same as those in the first embodiment.
The experiment adopts a double-blind cross design, the subjects are between 20 and 40 years old, after a washing period of two weeks and a rest period of one week, the probiotic composition is given for six weeks, and a endurance exercise test with fixed strength is given on the day of beginning and ending of taking, 5 groups are divided according to the maximum oxygen uptake, 16 persons are taken in each group, and the change of the whole body fat is measured; the probiotic compositions of each group were taken three times a day, one capsule at a time, and the dose and strain per group were the same as in example one.
(II) results
Six weeks after the probiotic composition was administered, the change in body fat after the endurance exercise test of fixed strength versus time was analyzed for each person, and the results are shown in fig. 3, in which the vertical axis represents the percentage change in body fat measured at the end of administration relative to the start of administration.
The results show that the live bacteria and the heat-induced killed bacteria can reduce the body fat, wherein the body fat of the low-dose group and the heat-induced killed bacteria is reduced by about 0.5 percent compared with that of the placebo group, the body fat of the live bacteria is reduced more obviously along with the increase of the dose, and the body fat of the high-dose group can be reduced by 1.5 percent, which indicates that the TWK10 has the body fat reducing effect no matter in the form of live bacteria or non-activated bacteria.
In summary, TWK10 has the effects of reducing post-exercise inflammation and body fat, and since TWK10 can reduce NLR or (and) PLR, NLR and PLR can also be used as diagnostic indicators and causes of many cancers, metastasis of diseases, and infections, and hyperlipidemia is one of the causes of systemic chronic inflammation, chronic diseases, cardiovascular diseases, etc., any implementation of the present invention to improve diseases or symptoms caused by NLR, PLR, or hyperlipidemia should be considered as included in the scope of the present invention.
Because the synergistic effect of reducing body fat and improving inflammation is achieved, the probiotic composition can reduce body fat and synchronously reduce systemic chronic inflammation after long-term administration, thereby achieving double and additive body improvement effects.
Probiotic compositions for use in the present invention may be in dosage forms including, but not limited to, solutions, emulsions, suspensions, powders, lozenges (tablets), pills, lozenges (lozenes), tablets (troche), chewing gum (chewing gum), capsules, and other similar or suitable dosage forms for use in the present invention.
The probiotic composition used in the present invention may optionally include other species as taught by the general knowledge in the art to which the present invention pertains, Lactobacillus (Lactobacillus sp.), Lactococcus (Lactococcus sp.), Pediococcus (Pediococcus sp.), Leuconostoc sp, Enterococcus (Enterococcus sp.), Streptococcus (Streptococcus sp.), bifidus (Bifidobacterium sp.), yeast (yeast sp.).
The probiotic composition used in the present invention may be a food composition, further formulated as a capsule, lozenge, beverage, powder or dairy product; the composition used in the invention can be further added with an edible material to prepare a food product or a health-care product. Wherein the edible material comprises, but is not limited to: water, fluid dairy, milk, concentrated milk; fermented dairy products such as yogurt (yogart), yogurt (sour milk), frozen yogurt (frozen yogart), lactobacillus fermented beverages; milk powder; ice cream; cheese; cheese; soymilk; fermenting the soymilk; vegetable and fruit juice; fruit juice; sports drinks; a dessert; jelly; a candy; infant food products; a health food; animal feed; chinese herbal medicine materials; dietary supplements, and the like.
The aforementioned composition used in the present invention may be a dietary supplement and may be administered to the user in the following manner: mixing with a suitable drinkable liquid, such as water, yogurt, milk or fruit juice; or may be mixed with solid or liquid food products. The dietary supplement may be in the form of tablets, pills, capsules, dragees (lozenes), granules, powders, suspensions, sachets, pastilles, candies, bars, syrups and corresponding administration forms, usually in unit dose form, and manufactured in a conventional manner for preparing dietary supplements.
In the present embodiments, the effective dosage varies depending on the combination therapy. Combination therapy may further include periodic therapy, varying depending on factors such as the composition, disease, physiological abnormality, physiological condition, etc. being co-administered.
The above-mentioned embodiments are merely illustrative of the technical ideas and features of the present invention, and the purpose thereof is to enable those skilled in the art to understand the contents of the present invention and to implement the same, but not to limit the scope of the present invention, i.e., all equivalent changes or modifications made in the spirit of the present invention should be covered by the scope of the present invention.
Claims (21)
1. The lactobacillus plantarum TWK10 is stored in China general microbiological culture collection center with the collection number of CGMCC13008 and used for preparing a probiotic composition for improving inflammation after exercise.
2. The use according to claim 1, wherein the improvement in post-exercise inflammation is a reduction in neutrophil/lymphocyte ratio or platelet/lymphocyte ratio.
3. Use according to claim 1, wherein the Lactobacillus plantarum TWK10 is a live or non-activated bacterium, which has been subjected to a physical or chemical treatment, wherein the physical treatment comprises thermal lethality.
4. The use of claim 3, wherein the Lactobacillus plantarum TWK10 is live, at a dose greater than or equal to 3x1010CFU/day.
5. The use of claim 4 at a dose greater than 1x1011CFU/day.
6. The use of claim 1, said probiotic composition comprising a pharmaceutically acceptable carrier, excipient, diluent.
7. The use of claim 1, wherein the probiotic composition is in a dosage form selected from the group consisting of a solution, a suspension, an emulsion, a powder, a lozenge, a pill, a syrup, a lozenge, a tablet, a chewing gum, a puree, and a capsule.
8. The use according to claim 1, wherein the probiotic composition is further formulated as a fluid dairy, a concentrated milk, a yogurt, a frozen yogurt, a fermented milk with lactobacilli, a milk powder, an ice cream, a cheese, a soy milk, a fermented soy milk, a vegetable juice, a fruit juice, a sports drink, a dessert, a jelly, a candy, an infant food, a health food, an animal feed, a herbal composition, a dietary supplement.
9. The use of claim 1, the probiotic composition comprising one or a combination of any of the following probiotic groups: lactobacillus, lactococcus, Pediococcus, Leuconostoc, enterococcus, Streptococcus, Bifidobacillus, and yeast.
10. Use of a Lactobacillus plantarum TWK10 having a accession number CGMCC13008 for the preparation of a pharmaceutical or food composition for the improvement of post-exercise inflammation.
11. Use of a probiotic composition for the preparation of a composition for improving diseases or conditions caused by an elevated neutrophil/lymphocyte ratio and platelet/lymphocyte ratio, comprising lactobacillus plantarum TWK10 having the accession number CGMCC 13008.
12. Use of lactobacillus plantarum TWK10 with the preservation number of CGMCC13008 in preparation of a probiotic composition for reducing body fat.
13. The use according to claim 12, wherein the body fat reduction is body fat reduction of the whole body.
14. The use according to claim 12, wherein the probiotic composition comprises a probiotic, which is a live bacterium, a non-activated bacterium or a combination thereof.
15. The use of claim 12, wherein lactobacillus plantarum TWK10 is administered in an amount greater than or equal to 3x1010CFU/day.
16. The use of claim 12, said probiotic composition comprising a pharmaceutically acceptable carrier, excipient, diluent.
17. The use of claim 12, wherein the probiotic composition is in a dosage form selected from the group consisting of a solution, a suspension, an emulsion, a powder, a lozenge, a pill, a syrup, a lozenge, a tablet, a chewing gum, a puree, and a capsule.
18. The use according to claim 12, wherein the probiotic composition is further formulated as a fluid dairy, a concentrated milk, a yogurt, a frozen yogurt, a fermented milk with lactobacilli, a milk powder, an ice cream, a cheese, a soy milk, a fermented soy milk, a vegetable juice, a fruit juice, a sports drink, a dessert, a jelly, a candy, an infant food, a health food, an animal feed, a herbal composition, a dietary supplement.
19. The use of claim 12, the probiotic composition comprising one or a combination of any of the following probiotic groups: lactobacillus species, Streptococcus species, Bifurcate bacteria species, yeast.
20. An application of a medical or food composition for reducing body fat comprises Lactobacillus plantarum TWK10 with the preservation number of CGMCC 13008.
21. Use of a probiotic composition for the preparation of a composition for ameliorating diseases or symptoms caused by body fat excess, comprising lactobacillus plantarum TWK10 having the accession number CGMCC 13008.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811519327.4A CN111297912A (en) | 2018-12-12 | 2018-12-12 | Application of lactobacillus plantarum TWK10 in preparing anti-post-exercise inflammation or body fat reducing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811519327.4A CN111297912A (en) | 2018-12-12 | 2018-12-12 | Application of lactobacillus plantarum TWK10 in preparing anti-post-exercise inflammation or body fat reducing composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111297912A true CN111297912A (en) | 2020-06-19 |
Family
ID=71146561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811519327.4A Pending CN111297912A (en) | 2018-12-12 | 2018-12-12 | Application of lactobacillus plantarum TWK10 in preparing anti-post-exercise inflammation or body fat reducing composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111297912A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180055893A1 (en) * | 2016-08-24 | 2018-03-01 | National Taiwan Sport University | Use of lactobacillus plantarum composition for manufacturing anti-fatigue probiotic composition for improve exercise performance |
| TWI634207B (en) * | 2017-10-20 | 2018-09-01 | 葡萄王生技股份有限公司 | A lactobacillus plantarum, composition, culturing method and use of decrease uric acid, improvement of allergy and/or decrease blood sugar |
| TWI636134B (en) * | 2017-10-20 | 2018-09-21 | 葡萄王生技股份有限公司 | A lactobacillus plantarum, composition, culturing method and use of decrease blood lipids and/or decrease function index |
| TWI636133B (en) * | 2017-10-20 | 2018-09-21 | 葡萄王生技股份有限公司 | A lactobacillus plantarum, composition, culturing method and use of elimination of body fat, reduction of hepatomegaly and/or anti-inflammatory |
| CN108624523A (en) * | 2017-03-20 | 2018-10-09 | 大江生医股份有限公司 | Lactobacillus germ TCI378 and its in fat reducing and improve functions of intestines and stomach application |
-
2018
- 2018-12-12 CN CN201811519327.4A patent/CN111297912A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180055893A1 (en) * | 2016-08-24 | 2018-03-01 | National Taiwan Sport University | Use of lactobacillus plantarum composition for manufacturing anti-fatigue probiotic composition for improve exercise performance |
| TW201808315A (en) * | 2016-08-24 | 2018-03-16 | 國立體育大學 | Use of lactobacillus plantarum for manufacturing anti-fatigue probiotic composition for improve execise performance |
| CN108624523A (en) * | 2017-03-20 | 2018-10-09 | 大江生医股份有限公司 | Lactobacillus germ TCI378 and its in fat reducing and improve functions of intestines and stomach application |
| TWI634207B (en) * | 2017-10-20 | 2018-09-01 | 葡萄王生技股份有限公司 | A lactobacillus plantarum, composition, culturing method and use of decrease uric acid, improvement of allergy and/or decrease blood sugar |
| TWI636134B (en) * | 2017-10-20 | 2018-09-21 | 葡萄王生技股份有限公司 | A lactobacillus plantarum, composition, culturing method and use of decrease blood lipids and/or decrease function index |
| TWI636133B (en) * | 2017-10-20 | 2018-09-21 | 葡萄王生技股份有限公司 | A lactobacillus plantarum, composition, culturing method and use of elimination of body fat, reduction of hepatomegaly and/or anti-inflammatory |
Non-Patent Citations (1)
| Title |
|---|
| 张山佳著: "《运动生物化学与健康营养》", 31 May 2017, 成都：电子科技大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9750775B2 (en) | Lactic acid bacterium-containing preparation | |
| KR102606952B1 (en) | Method of Lactobacillus Plantarum TWK10 composition for improving inflammation or reducing body fat after exercise | |
| JP5558475B2 (en) | Elderberry extract and L. Paracasei, L. Casei, L. Bulgarix or S. Composition comprising a combination with a strain of Thermophilus | |
| BRPI0808207A2 (en) | VEGETABLE FAT REDUCING AGENT | |
| JP7280069B2 (en) | A composition for preventing or improving functional gastrointestinal disorders, and pharmaceutical compositions and food and drink compositions using the composition for preventing or improving functional gastrointestinal disorders | |
| CN109310714A (en) | For treating and preventing gastrointestinal inflammatory Pu Shi bacillus faecalis bacterial strain CNCM I-4573 | |
| US10792317B2 (en) | Method for reducing body fat by administering Lactobacillus plantarum | |
| WO2019212997A1 (en) | Compositions and methods for biosynthetic preparation of urolithin compounds and use thereof | |
| AU2019241546B2 (en) | Sleep-promoting composition, and medicinal composition and food and beverage composition using said sleep-promoting composition | |
| CN111065274A (en) | Fermented milk for promoting increase of amino acid concentration in blood | |
| WO2011105403A1 (en) | Composition having bedsore-relieving effect | |
| JP2022044826A (en) | Oral composition | |
| CN111297912A (en) | Application of lactobacillus plantarum TWK10 in preparing anti-post-exercise inflammation or body fat reducing composition | |
| CN115702001A (en) | Composition for suppressing or improving depression | |
| TWI705817B (en) | Use of Lactobacillus embryo TWC10 for preparing anti-inflammatory pharmaceutical composition after exercise | |
| TWI824127B (en) | Use of Lactobacillus plantarum TWK10 in preparing pharmaceutical compositions for reducing body fat | |
| US20200188453A1 (en) | Method of a lactobacillus plantarum twk10 composition for improving inflammation after exercise | |
| JP2012126700A (en) | Gastrointestinal function promotor | |
| WO2018220917A1 (en) | Composition for fatigue recovery and/or prevention of fatigue accumulation | |
| JP7475155B2 (en) | Composition for improving endurance | |
| KR102502978B1 (en) | Composition for Anti-inflammation or Enhancing Immunity Comprising Surface Layer Protein of Lactic Acid Bacteria from Kefir | |
| JP7206623B2 (en) | Composition for prevention and improvement of glucose metabolism disorder | |
| WO2023176952A1 (en) | Composition for controlling proliferation of bacterium in intestine, and use thereof | |
| JP6785141B2 (en) | Basal metabolic rate enhancer | |
| JP2021127321A (en) | Composition for endurance improvement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |